IDA Ireland announced today that Dexcom, a global medtech company, plans to build its newest global manufacturing facility in Athenry, Galway.

The project is supported by the Irish Government through IDA Ireland and represents an investment of €300 million over five years and the potential to create up to 1,000 high skilled jobs over the same period.

Dexcom G7

In October 2022, Ireland was one of the initial launch markets globally for Dexcom G7, the company’s next-generation CGM system that offers a powerful yet simple way to help people gain greater control of their diabetes. The system’s low-profile, all-in-one wearable sends real-time glucose readings automatically to a compatible smart device or receiver, no painful finger sticks or burdensome scanning required. 

Dexcom G7 builds on the performance of Dexcom CGM, which is clinically proven to lower A1C and reduce hyper- and hypoglycemia.

Planning Permission

Subject to planning permission, the Ireland site will be Dexcom’s first manufacturing site in Europe, expanding upon the company’s existing capabilities in the US and Malaysia. The facility in Athenry will contain a highly automated manufacturing operation with an emphasis on green technologies. 

Dexcom expects to provide about 500 construction jobs while the facility is being built and up to 1,000 high tech graduate and technician level positions once the site is running at full capacity.

'Ambitious Growth Strategy'

“With the continued success of our Dexcom G7 in Europe, we are pursuing an ambitious growth strategy that requires increased manufacturing capacity to support our rapidly expanding European user base,” said Barry Regan, Executive Vice President of Global Operations at Dexcom. 

“Ireland has an exceptional talent pool and an established MedTech sector, making Athenry the perfect location for us to establish a new, state-of-the-art manufacturing facility.”

Source: www.businessworld.ie